LivaNova Plc LIVN 深 滬
已收盤 02-06 16:00:00 美东时间
66.56
+1.530
+2.35%
華盛通- 最 高66.92
- 今 開65.45
- 成交量 57.81万股
- 最 低 64.98
- 昨 收 65.03
- 總市值 36.35亿
- 52周最高 67.92
- 市盈率 靜 57.44
- 換手率 1.06%
- 52周最低 32.48
- 委 比 71.64%
- 總股本 5460.55万
- 歷史最高 131.54
- 量 比 0.66
- 振 幅 2.98%
- 歷史最低 23.58
- 每 手 1
- 風險率 8.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
Stifel Maintains Buy on LivaNova, Raises Price Target to $70
Stifel analyst Rick Wise maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $65 to $70.
01-07 22:18
美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
2025-12-22 15:05
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Mizuho Maintains Outperform on LivaNova, Raises Price Target to $72
Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $70 to $72.
2025-12-17 21:07
LivaNova To Present Eight Posters At AES Highlighting VNS Therapy's Seizure Reduction And Improved Outcomes In Drug-Resistant Epilepsy
Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant EpilepsyLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company,
2025-12-03 22:03
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
LivaNova Announces 2030 Financial Targets, Sees High-Single-Digit-Plus Revenue CAGR; Adjusted Annual Operating Margin Above 20% Over The Next 3-Years, Targeting High Twenties By 2030; EPS CAGR In The Low Double Digits To Mid-Teens; Adjusted Free Cash Flow Conversion Above 80%
Provides 2030 Targets for Revenue and EPS GrowthLivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap and long-range
2025-11-13 04:30
LivaNova Raises FY2025 Adj EPS Guidance from $3.70-$3.80 to $3.80-$3.90 vs $3.75 Est, Company Now Expects FY25 Revenue To Grow Between 8.5%-9.5% (Versus 8%-9% Prior)
LivaNova (NASDAQ:LIVN) raises FY2025 Adj EPS guidance from $3.70-$3.80 to $3.80-$3.90 vs $3.75 analyst estimate..
2025-11-05 19:03
